222 related articles for article (PubMed ID: 28751153)
1. CCR5-edited gene therapies for HIV cure: Closing the door to viral entry.
Haworth KG; Peterson CW; Kiem HP
Cytotherapy; 2017 Nov; 19(11):1325-1338. PubMed ID: 28751153
[TBL] [Abstract][Full Text] [Related]
2. CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy.
Allers K; Schneider T
Curr Opin Virol; 2015 Oct; 14():24-9. PubMed ID: 26143158
[TBL] [Abstract][Full Text] [Related]
3. CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia.
Xu L; Wang J; Liu Y; Xie L; Su B; Mou D; Wang L; Liu T; Wang X; Zhang B; Zhao L; Hu L; Ning H; Zhang Y; Deng K; Liu L; Lu X; Zhang T; Xu J; Li C; Wu H; Deng H; Chen H
N Engl J Med; 2019 Sep; 381(13):1240-1247. PubMed ID: 31509667
[TBL] [Abstract][Full Text] [Related]
4. Designer Nucleases: Gene-Editing Therapies using CCR5 as an Emerging Target in HIV.
Almeida MJ; Matos A
Curr HIV Res; 2019; 17(5):306-323. PubMed ID: 31652113
[TBL] [Abstract][Full Text] [Related]
5. A simultaneous knockout knockin genome editing strategy in HSPCs potently inhibits CCR5- and CXCR4-tropic HIV-1 infection.
Dudek AM; Feist WN; Sasu EJ; Luna SE; Ben-Efraim K; Bak RO; Cepika AM; Porteus MH
Cell Stem Cell; 2024 Apr; 31(4):499-518.e6. PubMed ID: 38579682
[TBL] [Abstract][Full Text] [Related]
6. Resistance to human immunodeficiency virus type 1 (HIV-1) generated by lentivirus vector-mediated delivery of the CCR5{Delta}32 gene despite detectable expression of the HIV-1 co-receptors.
Jin Q; Marsh J; Cornetta K; Alkhatib G
J Gen Virol; 2008 Oct; 89(Pt 10):2611-2621. PubMed ID: 18796731
[TBL] [Abstract][Full Text] [Related]
7. CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report.
Duarte RF; Salgado M; Sánchez-Ortega I; Arnan M; Canals C; Domingo-Domenech E; Fernández-de-Sevilla A; González-Barca E; Morón-López S; Nogues N; Patiño B; Puertas MC; Clotet B; Petz LD; Querol S; Martinez-Picado J
Lancet HIV; 2015 Jun; 2(6):e236-42. PubMed ID: 26423196
[TBL] [Abstract][Full Text] [Related]
8. Establishment of mouse leukemia cell lines expressing human CD4/CCR5 using lentiviral vectors.
Li YJ; ZhuGe FY; Zeng CC; He JY; Tan N; Liang J
Virus Genes; 2017 Apr; 53(2):197-204. PubMed ID: 28028680
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1.
Khamaikawin W; Saisawang C; Tassaneetrithep B; Bhukhai K; Phanthong P; Borwornpinyo S; Phuphuakrat A; Pasomsub E; Chaisavaneeyakorn S; Anurathapan U; Apiwattanakul N; Hongeng S
Sci Rep; 2024 May; 14(1):10852. PubMed ID: 38741006
[TBL] [Abstract][Full Text] [Related]
10. CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection.
Wang W; Ye C; Liu J; Zhang D; Kimata JT; Zhou P
PLoS One; 2014; 9(12):e115987. PubMed ID: 25541967
[TBL] [Abstract][Full Text] [Related]
11. Antiretrovirals to CCR5 CRISPR/Cas9 gene editing - A paradigm shift chasing an HIV cure.
Khan A; Paneerselvam N; Lawson BR
Clin Immunol; 2023 Oct; 255():109741. PubMed ID: 37611838
[TBL] [Abstract][Full Text] [Related]
12. Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy.
Bai J; Rossi J; Akkina R
AIDS Res Hum Retroviruses; 2001 Mar; 17(5):385-99. PubMed ID: 11282007
[TBL] [Abstract][Full Text] [Related]
13. mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5.
Mock U; Machowicz R; Hauber I; Horn S; Abramowski P; Berdien B; Hauber J; Fehse B
Nucleic Acids Res; 2015 Jun; 43(11):5560-71. PubMed ID: 25964300
[TBL] [Abstract][Full Text] [Related]
14. Gene Therapy to Cure HIV: Where to from Here?
Johnston R
AIDS Patient Care STDS; 2016 Dec; 30(12):531-533. PubMed ID: 27905839
[TBL] [Abstract][Full Text] [Related]
15. CCR5-targeted hematopoietic stem cell gene approaches for HIV disease: current progress and future prospects.
Lai Y
Curr Stem Cell Res Ther; 2012 Jul; 7(4):310-7. PubMed ID: 22486585
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Evaluation of a Novel TALEN Targeting CCR5 Confirms Efficacy and Safety in Conferring Resistance to HIV-1 Infection.
Romito M; Juillerat A; Kok YL; Hildenbeutel M; Rhiel M; Andrieux G; Geiger J; Rudolph C; Mussolino C; Duclert A; Metzner KJ; Duchateau P; Cathomen T; Cornu TI
Biotechnol J; 2021 Jan; 16(1):e2000023. PubMed ID: 33103367
[TBL] [Abstract][Full Text] [Related]
17. Clinical Applications of Genome Editing to HIV Cure.
Wang CX; Cannon PM
AIDS Patient Care STDS; 2016 Dec; 30(12):539-544. PubMed ID: 27854119
[TBL] [Abstract][Full Text] [Related]
18. Analysis and dissociation of anti-HIV effects of shRNA to CCR5 and the fusion inhibitor C46.
Ledger S; Howe A; Turville S; Aggarwal A; Savkovic B; Ong A; Wolstein O; Boyd M; Millington M; Gorry PR; Murray JM; Symonds G
J Gene Med; 2018 Feb; 20(2-3):e3006. PubMed ID: 29552747
[TBL] [Abstract][Full Text] [Related]
19. The Strategies and Challenges of CCR5 Gene Editing in Hematopoietic Stem and Progenitor Cells for the Treatment of HIV.
Karuppusamy KV; Babu P; Thangavel S
Stem Cell Rev Rep; 2021 Oct; 17(5):1607-1618. PubMed ID: 33788143
[TBL] [Abstract][Full Text] [Related]
20. Cell-Delivered Entry Inhibitors for HIV-1: CCR5 Downregulation and Blocking Virus/Membrane Fusion in Defending the Host Cell Population.
Symonds G; Bartlett JS; Kiem HP; Tsie M; Breton L
AIDS Patient Care STDS; 2016 Dec; 30(12):545-550. PubMed ID: 27905841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
